André N. Vis

6.1k total citations · 1 hit paper
177 papers, 4.0k citations indexed

About

André N. Vis is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, André N. Vis has authored 177 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 132 papers in Pulmonary and Respiratory Medicine, 43 papers in Surgery and 41 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in André N. Vis's work include Prostate Cancer Treatment and Research (113 papers), Prostate Cancer Diagnosis and Treatment (105 papers) and Bladder and Urothelial Cancer Treatments (32 papers). André N. Vis is often cited by papers focused on Prostate Cancer Treatment and Research (113 papers), Prostate Cancer Diagnosis and Treatment (105 papers) and Bladder and Urothelial Cancer Treatments (32 papers). André N. Vis collaborates with scholars based in Netherlands, United Kingdom and United States. André N. Vis's co-authors include Theodorus van der Kwast, Fritz H. Schröder, R. Jeroen A. van Moorselaar, Ries Kranse, Robert F. Hoedemaeker, Bas W.G. van Rhijn, Ellen C. Zwarthoff, Daniela E. Oprea‐Lager, Jakko A. Nieuwenhuijzen and Egbert R. Boevé and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

André N. Vis

161 papers receiving 3.9k citations

Hit Papers

Effect on Survival of Androgen Deprivation Therapy Alone ... 2018 2026 2020 2023 2018 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial
    2018 336 citations Liselotte M.S. Boevé, Maarten C.C.M. Hulshof et al. European Urology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
André N. Vis Netherlands 34 2.6k 1.2k 917 637 551 177 4.0k
Antti Rannikko Finland 32 2.8k 1.1× 860 0.7× 1.1k 1.2× 377 0.6× 762 1.4× 148 4.4k
Chris H. Bangma Netherlands 34 2.7k 1.0× 811 0.7× 1.3k 1.4× 584 0.9× 341 0.6× 99 4.4k
Romain Mathiéu France 31 1.8k 0.7× 1.2k 0.9× 636 0.7× 401 0.6× 734 1.3× 246 3.5k
Vincent J. Gnanapragasam United Kingdom 37 2.4k 0.9× 429 0.3× 956 1.0× 843 1.3× 472 0.9× 143 3.6k
Juan Moróte Spain 37 2.8k 1.1× 1.0k 0.8× 1.1k 1.2× 378 0.6× 1.1k 2.0× 358 4.8k
Bernard Malavaud France 39 1.5k 0.6× 1.4k 1.1× 1.3k 1.4× 344 0.5× 488 0.9× 224 4.7k
Sisto Perdonà Italy 39 1.9k 0.8× 1.3k 1.1× 792 0.9× 218 0.3× 599 1.1× 134 3.8k
Nicolas Barry Delongchamps France 30 2.2k 0.9× 485 0.4× 495 0.5× 613 1.0× 428 0.8× 138 3.3k
Bruce L. Dalkin United States 33 2.7k 1.1× 721 0.6× 769 0.8× 215 0.3× 631 1.1× 69 4.2k
Antoine Valéri France 30 1.8k 0.7× 951 0.8× 1.1k 1.2× 217 0.3× 528 1.0× 117 3.0k

Countries citing papers authored by André N. Vis

Since Specialization
Citations

This map shows the geographic impact of André N. Vis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by André N. Vis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites André N. Vis more than expected).

Fields of papers citing papers by André N. Vis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by André N. Vis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by André N. Vis. The network helps show where André N. Vis may publish in the future.

Co-authorship network of co-authors of André N. Vis

This figure shows the co-authorship network connecting the top 25 collaborators of André N. Vis. A scholar is included among the top collaborators of André N. Vis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with André N. Vis. André N. Vis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vis, André N., et al.. (2025). Exploring the Flare Phenomenon in Patients with Castration-Resistant Prostate Cancer: Enzalutamide-Induced PSMA Upregulation Observed on PSMA PET. Journal of Nuclear Medicine. 66(3). 373–376. 1 indexed citations
2.
Contieri, Roberto, Matteo Droghetti, Maarten L. Donswijk, et al.. (2024). Staging Accuracy and Prognostic Value of Prostate-Specific Membrane Antigen PET/CT Strongly Depends on Lymph Node Tumor Burden. Journal of Clinical Medicine. 13(21). 6534–6534. 2 indexed citations
3.
Heerink, Wouter J., Harald C. Groen, H.G. Van Der Poel, et al.. (2024). Feasibility of Image-guided Navigation with Electromagnetic Tracking During Robot-assisted Sentinel Node Biopsy: A Prospective Study. European Urology. 87(4). 482–490. 3 indexed citations
4.
5.
Leeuwen, Pim J. van, Maurits Wondergem, Thierry N. Boellaard, et al.. (2024). A Systematic Review on the Diagnostic Value of Fibroblast Activation Protein Inhibitor PET/CT in Genitourinary Cancers. Journal of Nuclear Medicine. 65(6). 888–896. 9 indexed citations
6.
Donswijk, Maarten L., et al.. (2024). The intra- and interobserver variability of PSMA-expression scores in patients with primary prostate cancer. EJNMMI Research. 14(1). 99–99. 2 indexed citations
7.
Barros, Hilda A. de, André N. Vis, Andries M. Bergman, et al.. (2023). Treating Primary Node-Positive Prostate Cancer: A Scoping Review of Available Treatment Options. Cancers. 15(11). 2962–2962. 2 indexed citations
8.
Barwari, Kurdo, A.M.E. Claessen, Vincent van der Noort, et al.. (2023). Histopathological Concordance between Prostate Biopsies and Radical Prostatectomy Specimens – Implications of Transrectal and Transperineal Biopsy Approaches. European Urology Open Science. 57. S60–S61. 1 indexed citations
9.
Mehra, Niven, André N. Vis, Joyce M. van Dodewaard-de Jong, et al.. (2023). The conundrum of treating metastatic hormone sensitive prostate cancer. European Urology Open Science. 57. S161–S161.
10.
Houwink, Aletta P. I., Jakko A. Nieuwenhuijzen, Ton A. Roeleveld, et al.. (2021). Intraoperative Strategies to Reduce Catheter-Related Bladder Discomfort in the Early Postoperative Period after Robot-Assisted Radical Prostatectomy. The Journal of Urology. 205(6). 1671–1680. 3 indexed citations
11.
Oprea‐Lager, Daniela E., André N. Vis, Mariëlle J. Wondergem, et al.. (2021). Reproducibility of tumor staging depends on the applied PSMA-radiotracer - A retrospective analysis on the interobserver variability of PSMA-PET/CT. European Urology Open Science. 33. S194–S197. 1 indexed citations
12.
Meijer, Dennie, B.H.E. Jansen, Maurits Wondergem, et al.. (2020). Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer. PLoS ONE. 15(10). e0239414–e0239414. 9 indexed citations
13.
Bodar, Yves J. L., B.H.E. Jansen, Gerben J.C. Zwezerijnen, et al.. (2020). Detection of intraprostatic tumor localisation with 18-Fluorine Prostate-Specific Membrane Antigen (PSMA) PET/CT compared to radical prostatectomy specimens: Is PSMA-targeted biopsy feasible? the DeTeCT trial. European Urology Open Science. 19. e470–e471. 1 indexed citations
14.
Jansen, B.H.E., Yves J. L. Bodar, Gerben J.C. Zwezerijnen, et al.. (2020). Prospective evaluation of pelvic lymph node staging with 18fluorine prostate-specific membrane antigen PET/CT prior to extended lymph node dissection in primary prostate cancer – the SALT trial. European Urology Open Science. 19. e1699–e1699. 1 indexed citations
15.
Bosschieter, Judith, Anouk E. Hentschel, C. Dilara Savci‐Heijink, et al.. (2019). Objectifying grade in Ta-T1 urothelial carcinomas of the bladder using proliferative and quantitative markers: A multicentre study in 310 bladder tumors. Urologic Oncology Seminars and Original Investigations. 37(8). 530.e1–530.e8. 3 indexed citations
16.
Voskuilen, Charlotte S., Judith Bosschieter, Erik van Werkhoven, et al.. (2019). Long-term survival and complications following bladder-preserving brachytherapy in patients with cT1-T2 bladder cancer. Radiotherapy and Oncology. 141. 130–136. 11 indexed citations
17.
Bosschieter, Judith, Jakko A. Nieuwenhuijzen, André N. Vis, et al.. (2018). An immediate, single intravesical instillation of mitomycin C is of benefit in patients with non–muscle-invasive bladder cancer irrespective of prognostic risk groups. Urologic Oncology Seminars and Original Investigations. 36(9). 400.e7–400.e14. 13 indexed citations
18.
Bosschieter, Judith, André N. Vis, Henk G. van der Poel, et al.. (2017). Robot-assisted Laparoscopic Implantation of Brachytherapy Catheters in Bladder Cancer. European Urology. 74(3). 369–375. 5 indexed citations
19.
Sluis, Tim M. van der, R. Jeroen A. van Moorselaar, E.J.H. Meuleman, et al.. (2013). Relationship Between Body Mass Index and Serum Testosterone Concentration in Patients Receiving Luteinizing Hormone-releasing Hormone Agonist Therapy for Prostate Cancer. Urology. 81(5). 1005–1009. 5 indexed citations
20.
Sluis, Tim M. van der, André N. Vis, R. Jeroen A. van Moorselaar, et al.. (2011). Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer. British Journal of Urology. 109(2). 176–182. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Antti Rannikko Breakdown of academic impact, for papers by Chris H. Bangma Breakdown of academic impact, for papers by Romain Mathiéu Breakdown of academic impact, for papers by Vincent J. Gnanapragasam Breakdown of academic impact, for papers by Juan Moróte Breakdown of academic impact, for papers by Bernard Malavaud Breakdown of academic impact, for papers by Sisto Perdonà Breakdown of academic impact, for papers by Nicolas Barry Delongchamps Breakdown of academic impact, for papers by Bruce L. Dalkin Breakdown of academic impact, for papers by Antoine Valéri
Rankless by CCL
2026